Sunday, November 15, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
News articleNasdaq· March 3, 2026

Stocks Sink as Crude Oil Surge Rattles Markets

View original at nasdaq.com
Stocks Sink as Crude Oil Surge Rattles Markets The S&P 500 Index ($SPX) (SPY) today is down -2.18%, the Dow Jones Industrial Average ($DOWI) (DIA) is down -2.27%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down -2.37%…
Opening lines of the source · Nasdaq · short snapshot: read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • We will set fire to any ship attempting to pass through the Strait of Hormuz

    80% confidence
  • Combat operations against Iran could last for weeks until all objectives were completed

    80% confidence
  • Additional Fed interest rate cuts will be warranted if inflation slows further once most of the impact of tariffs has passed

    80% confidence
  • The real-time risk premium for crude oil is $18/bbl, corresponding to the impact of a six-week full halt to tanker traffic in the Strait of Hormuz

    80% confidence
  • Inflation has been above the Fed's objective for nearly five years now, so I don't think we have room to be complacent

    80% confidence
  • Excluding the Magnificent Seven megacap technology stocks, Q4 earnings are expected to increase by 4.6%

    80% confidence
  • Iran's leaders should capitulate

    80% confidence
  • S&P earnings growth is expected to climb by 8.4% in Q4, marking the tenth consecutive quarter of year-over-year growth

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,997
facts traced to their source, and we flag the ones that don't hold up.
101 entities tracked4,997 facts checked against source5,585 source documents archived
Query this data → isubstrate.com